Industry
Biotechnology
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Loading...
Open
1.06
Mkt cap
29M
Volume
2M
High
1.11
P/E Ratio
-0.68
52-wk high
6.00
Low
1.01
Div yield
N/A
52-wk low
0.86
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 12:08 pm
Portfolio Pulse from Avi Kapoor
October 30, 2024 | 10:16 am
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 5:42 pm
Portfolio Pulse from Benzinga Insights
October 10, 2024 | 4:31 pm
Portfolio Pulse from Vandana Singh
October 10, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
October 10, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:03 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.